Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04053634




Registration number
NCT04053634
Ethics application status
Date submitted
16/07/2019
Date registered
12/08/2019
Date last updated
9/08/2024

Titles & IDs
Public title
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Scientific title
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)
Secondary ID [1] 0 0
2019-001800-39
Secondary ID [2] 0 0
D3251C00014
Universal Trial Number (UTN)
Trial acronym
RESOLUTE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Chronic obstructive pulmonary disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Benralizumab
Treatment: Other - Placebo

Experimental: Benralizumab - Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks

Placebo comparator: Placebo - Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks


Treatment: Other: Benralizumab
Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

Treatment: Other: Placebo
Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized rate of moderate or severe COPD exacerbations
Timepoint [1] 0 0
Over first 56 weeks
Secondary outcome [1] 0 0
Annualized rate of severe COPD exacerbations
Timepoint [1] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [2] 0 0
Annualized rate of COPD exacerbations that are associated with an emergency room/emergency department visit or a hospitalization
Timepoint [2] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [3] 0 0
Time to first COPD exacerbation
Timepoint [3] 0 0
During first 56 weeks
Secondary outcome [4] 0 0
Change from baseline in SGRQ total and domain scores
Timepoint [4] 0 0
up to 56 weeks
Secondary outcome [5] 0 0
Change from baseline in E-RS:COPD total and domain scores
Timepoint [5] 0 0
up to 56 weeks
Secondary outcome [6] 0 0
Change from baseline in pre-dose/pre-bronchodilator FEV1
Timepoint [6] 0 0
up to 56 weeks
Secondary outcome [7] 0 0
All cause and respiratory-related mortality rate
Timepoint [7] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [8] 0 0
Annual rate of hospitalizations due to COPD
Timepoint [8] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [9] 0 0
Serum benralizumab concentration as a measure of pharmacokinetics
Timepoint [9] 0 0
up to 56 weeks
Secondary outcome [10] 0 0
Anti-drug antibodies (ADA) as a measure of immunogenicity
Timepoint [10] 0 0
up to 56 weeks
Secondary outcome [11] 0 0
Change from baseline in CAT total score
Timepoint [11] 0 0
up to 56 weeks
Secondary outcome [12] 0 0
Length of hospital stay
Timepoint [12] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [13] 0 0
ICU (Intensive Care Unit) days
Timepoint [13] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [14] 0 0
Annual rate of hospitalizations and emergency department visits combined
Timepoint [14] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [15] 0 0
Annual rate of unscheduled outpatient visits including unscheduled visits to study sites
Timepoint [15] 0 0
Minimum of 1 year and an average of 2 years
Secondary outcome [16] 0 0
Annual rate of unscheduled healthcare encounters
Timepoint [16] 0 0
Minimum of 1 year and and average of 2 years

Eligibility
Key inclusion criteria
1. Provision of informed consent
2. Age 40 to 85 years
3. Male and/or female.
4. Current or former smoker with a tobacco history of =10 pack-years.
5. History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC<0.70 and FEV1 =65% of predicted normal value.
6. Documented history of 2 or more COPD exacerbations that required treatment with systemic corticosteroids and/or hospitalization within 52 weeks prior to enrollment.

1. Exacerbations treated with antibiotics alone are excluded unless accompanied by treatment with systemic corticosteroids and/or hospitalization.
2. Hospitalization is defined as an inpatient admission =24 hours
3. Previous exacerbations should be confirmed to have occurred while on stable triple therapy for COPD.
4. At least one qualifying COPD exacerbation should occur while on stable uninterrupted triple therapy prior to enrolment.
7. Documented use of triple (ICS/LABA/LAMA) background therapy for COPD for =3 months immediately prior to enrollment.

1. Treatment with at least double inhaled therapy containing ICS (e.g. ICS/LABA or ICS/LAMA) for the remaining of 52 weeks prior to enrolment. Use of LABA/LAMA is allowed if ICS cannot be tolerated.
2. ICS in a dose approved for COPD or equivalent to =250 mcg of fluticasone propionate daily.
3. Total cumulative duration of not being on double or triple background therapy must not exceed 2 months.
4. Stable therapy/doses for the last 3 months prior to randomization.
8. Blood eosinophil count =300/µL at screening and documented historical eosinophil count of =150/µL within 52 weeks of enrollment (or repeated testing during run-in).
9. CAT total score =15 at Visit 1.
10. Negative pregnancy test for females of childbearing potential (WOCBP) at Visit 1.
11. Women of childbearing potential (WOCBP) must agree to use a highly effective method of birth control from enrollment throughout the study and within 12 weeks after last dose of IP.

Women not of childbearing potential are defined as women who are either permanently sterilized or postmenopausal (confirmed by FSH test for women <50 years).
Minimum age
40 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Clinically important pulmonary disease other than COPD
2. Current diagnosis of asthma, prior history of asthma or asthma-COPD overlap according to GINA/GOLD. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved before the age of 18.
3. Radiological findings of a respiratory disease other than COPD contributing to respiratory symptoms. Solitary pulmonary nodules without appropriate follow up or findings of acute infection.
4. Another pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
5. Any unstable disorder that could affect patient safety, study findings or the patient's ability to complete the study.
6. Any clinically significant abnormal findings in physical examination, vital signs, ECG, laboratory tests could affect patient safety, study findings or the patient's ability to complete the study.
7. Cor pulmonale and/or right ventricular failure.
8. Long-term treatment with oxygen >4.0 L/min and/or oxyhemoglobin saturation <89% while breathing supplemental oxygen.
9. Use of any non-invasive positive pressure ventilation device (NIPPV). Note: use of CPAP for Sleep Apnea Syndrome is allowed.
10. Known immunodeficiency disorder, including positive HIV-1/2 testing.
11. Active liver disease. Chronic stable hepatitis B and C (including positive HBsAg or hepatitis C antibody testing), or other stable chronic liver disease are acceptable.
12. ALT or AST =3 times the upper limit of normal, confirmed by repeated testing during the run-in period.
13. Helminth parasitic infection within 24 weeks prior to enrollment, not treated or failed to respond to standard of care therapy.
14. Alcohol or drug abuse within the past year, which may compromise the study data.
15. Malignancy, current or within the past 5 years, except for adequately treated non invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than 1 year prior to Visit 1. Suspected malignancy or undefined neoplasms.
16. Evidence of active tuberculosis, as judged by investigator. Patients with a recent (within 2 years) first-time or newly positive PPD or Quantiferon test need to complete an appropriate course of treatment before enrollment. Evaluation will be according to the local standard of care.
17. Participation, or planned participation, in intensive COPD rehabilitation program (maintenance phase of a rehabilitation is allowed).
18. History of surgical or endoscopic lung volume reduction within the 6 months prior to enrollment. History of partial or total lung resection (single lobe or segmentectomy is acceptable).
19. Scheduled major surgical procedure during the study. Minor elective procedures are allowed.
20. History of anaphylaxis to any biologic therapy or vaccine.
21. Receipt of blood products or immunoglobulins within 30 days prior to randomization.
22. Receipt of marketed or investigational biologic product within 4 months or 5 half-lives prior to randomization, whichever is longer. Exception: Patients on stable therapy for 3 months before randomization who intend to stay on treatment throughout the study with marketed biologic products that are not likely to interfere with the safety assessment and/or efficacy of benralizumab, for example, for the treatment of osteoporosis, migraine, pain, diabetes, obesity, ocular, cardiovascular, or metabolic diseases, can participate in the study.
23. Receipt of live attenuated vaccines 30 days prior to randomization.
24. Chronic use of immunosuppressive medication or expected need for chronic use during the study.
25. Chronic use of antibiotics if duration of treatment is <9 months prior to randomization. Chronic macrolide or other antibiotic therapy is allowed provided the patient has been on stable dose/regimen for =9 months prior to randomization and has had =2 COPD exacerbations while on stable therapy.
26. Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to enrollment.
27. Receipt of benralizumab within 12 months prior to enrollment.
28. Known history of allergy or reaction to any component of the IP formulation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/08/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/08/2025
Actual
Sample size
Target
Accrual to date
Final
689
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Caringbah
Recruitment hospital [2] 0 0
Research Site - Melbourne
Recruitment hospital [3] 0 0
Research Site - South Brisbane
Recruitment hospital [4] 0 0
Research Site - Southport
Recruitment hospital [5] 0 0
Research Site - Spearwood
Recruitment postcode(s) [1] 0 0
2229 - Caringbah
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
4215 - Southport
Recruitment postcode(s) [5] 0 0
6163 - Spearwood
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
South Dakota
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
West Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Wisconsin
Country [32] 0 0
Argentina
State/province [32] 0 0
Buenos Aires
Country [33] 0 0
Argentina
State/province [33] 0 0
Caba
Country [34] 0 0
Argentina
State/province [34] 0 0
Ciudad Autónoma de Buenos Aire
Country [35] 0 0
Argentina
State/province [35] 0 0
Ciudad de Buenos Aires
Country [36] 0 0
Argentina
State/province [36] 0 0
Córdoba
Country [37] 0 0
Argentina
State/province [37] 0 0
Florencio Varela
Country [38] 0 0
Argentina
State/province [38] 0 0
Florida
Country [39] 0 0
Argentina
State/province [39] 0 0
Mar del Plata
Country [40] 0 0
Argentina
State/province [40] 0 0
Mendoza
Country [41] 0 0
Argentina
State/province [41] 0 0
San Fernando
Country [42] 0 0
Argentina
State/province [42] 0 0
San Miguel de Tucuman
Country [43] 0 0
Austria
State/province [43] 0 0
Bad Ischl
Country [44] 0 0
Austria
State/province [44] 0 0
Bludenz
Country [45] 0 0
Austria
State/province [45] 0 0
Feldbach
Country [46] 0 0
Austria
State/province [46] 0 0
Grieskirchen
Country [47] 0 0
Austria
State/province [47] 0 0
Linz
Country [48] 0 0
Austria
State/province [48] 0 0
Thalheim
Country [49] 0 0
Belgium
State/province [49] 0 0
Edegem
Country [50] 0 0
Belgium
State/province [50] 0 0
Erpent
Country [51] 0 0
Brazil
State/province [51] 0 0
Blumenau
Country [52] 0 0
Brazil
State/province [52] 0 0
Botucatu
Country [53] 0 0
Brazil
State/province [53] 0 0
Florianópolis
Country [54] 0 0
Brazil
State/province [54] 0 0
Maringa
Country [55] 0 0
Brazil
State/province [55] 0 0
Porto Alegre
Country [56] 0 0
Brazil
State/province [56] 0 0
Santo Andre
Country [57] 0 0
Brazil
State/province [57] 0 0
Sao Bernardo do Campo
Country [58] 0 0
Brazil
State/province [58] 0 0
Sao Paulo
Country [59] 0 0
Brazil
State/province [59] 0 0
Sorocaba
Country [60] 0 0
Bulgaria
State/province [60] 0 0
Kozloduy
Country [61] 0 0
Bulgaria
State/province [61] 0 0
Ruse
Country [62] 0 0
Bulgaria
State/province [62] 0 0
Stara Zagora
Country [63] 0 0
Canada
State/province [63] 0 0
Alberta
Country [64] 0 0
Canada
State/province [64] 0 0
NF
Country [65] 0 0
Canada
State/province [65] 0 0
Ontario
Country [66] 0 0
Canada
State/province [66] 0 0
Quebec
Country [67] 0 0
Canada
State/province [67] 0 0
Saskatchewan
Country [68] 0 0
Canada
State/province [68] 0 0
Chicoutimi
Country [69] 0 0
Chile
State/province [69] 0 0
Curico
Country [70] 0 0
Chile
State/province [70] 0 0
Quillota
Country [71] 0 0
Chile
State/province [71] 0 0
Santiago
Country [72] 0 0
Chile
State/province [72] 0 0
Talca
Country [73] 0 0
China
State/province [73] 0 0
Baotou
Country [74] 0 0
China
State/province [74] 0 0
Beijing
Country [75] 0 0
China
State/province [75] 0 0
Changsha
Country [76] 0 0
China
State/province [76] 0 0
Chengdu
Country [77] 0 0
China
State/province [77] 0 0
Chongqing
Country [78] 0 0
China
State/province [78] 0 0
Ganzhou
Country [79] 0 0
China
State/province [79] 0 0
Guangzhou
Country [80] 0 0
China
State/province [80] 0 0
Guiyang
Country [81] 0 0
China
State/province [81] 0 0
Haikou
Country [82] 0 0
China
State/province [82] 0 0
Hebei
Country [83] 0 0
China
State/province [83] 0 0
Hefei
Country [84] 0 0
China
State/province [84] 0 0
Hohhot
Country [85] 0 0
China
State/province [85] 0 0
Linhai
Country [86] 0 0
China
State/province [86] 0 0
Nanchang
Country [87] 0 0
China
State/province [87] 0 0
Shanghai
Country [88] 0 0
China
State/province [88] 0 0
Shenzhen
Country [89] 0 0
China
State/province [89] 0 0
Suzhou
Country [90] 0 0
China
State/province [90] 0 0
Urumqi
Country [91] 0 0
China
State/province [91] 0 0
Wenzhou
Country [92] 0 0
China
State/province [92] 0 0
Wuhan
Country [93] 0 0
China
State/province [93] 0 0
Xi'an
Country [94] 0 0
China
State/province [94] 0 0
Yinchuan
Country [95] 0 0
China
State/province [95] 0 0
Zhanjiang
Country [96] 0 0
China
State/province [96] 0 0
Zhengzhou
Country [97] 0 0
Colombia
State/province [97] 0 0
Barranquilla
Country [98] 0 0
Colombia
State/province [98] 0 0
Cali
Country [99] 0 0
Colombia
State/province [99] 0 0
Floridablanca
Country [100] 0 0
Colombia
State/province [100] 0 0
Medellin
Country [101] 0 0
Colombia
State/province [101] 0 0
Pereira
Country [102] 0 0
Colombia
State/province [102] 0 0
Zipaquira
Country [103] 0 0
Czechia
State/province [103] 0 0
Brandys nad Labem
Country [104] 0 0
Czechia
State/province [104] 0 0
Jindrichuv Hradec
Country [105] 0 0
Czechia
State/province [105] 0 0
Ostrava
Country [106] 0 0
Czechia
State/province [106] 0 0
Rokycany
Country [107] 0 0
Czechia
State/province [107] 0 0
Teplice
Country [108] 0 0
Denmark
State/province [108] 0 0
Hvidovre
Country [109] 0 0
Denmark
State/province [109] 0 0
København NV
Country [110] 0 0
Denmark
State/province [110] 0 0
Odense C
Country [111] 0 0
Denmark
State/province [111] 0 0
Roskilde
Country [112] 0 0
Denmark
State/province [112] 0 0
Vejle
Country [113] 0 0
Denmark
State/province [113] 0 0
Ålborg
Country [114] 0 0
Germany
State/province [114] 0 0
Bamberg
Country [115] 0 0
Germany
State/province [115] 0 0
Berlin
Country [116] 0 0
Germany
State/province [116] 0 0
Darmstadt
Country [117] 0 0
Germany
State/province [117] 0 0
Hamburg
Country [118] 0 0
Germany
State/province [118] 0 0
Hannover
Country [119] 0 0
Germany
State/province [119] 0 0
Koblenz
Country [120] 0 0
Germany
State/province [120] 0 0
Köln
Country [121] 0 0
Germany
State/province [121] 0 0
Leipzig
Country [122] 0 0
Germany
State/province [122] 0 0
Marburg
Country [123] 0 0
Germany
State/province [123] 0 0
Neu-Isenburg
Country [124] 0 0
Germany
State/province [124] 0 0
Peine
Country [125] 0 0
Germany
State/province [125] 0 0
Potsdam
Country [126] 0 0
Germany
State/province [126] 0 0
Rheine
Country [127] 0 0
Germany
State/province [127] 0 0
Warendorf
Country [128] 0 0
Greece
State/province [128] 0 0
Athens
Country [129] 0 0
Greece
State/province [129] 0 0
Exohi Thessaloniki
Country [130] 0 0
Greece
State/province [130] 0 0
Ioannina
Country [131] 0 0
Greece
State/province [131] 0 0
Thessaloniki
Country [132] 0 0
Hungary
State/province [132] 0 0
Balassagyarmat
Country [133] 0 0
Hungary
State/province [133] 0 0
Budapest
Country [134] 0 0
Hungary
State/province [134] 0 0
Edelény
Country [135] 0 0
Hungary
State/province [135] 0 0
Encs
Country [136] 0 0
Hungary
State/province [136] 0 0
Gödöllo
Country [137] 0 0
Hungary
State/province [137] 0 0
Hajdúnánás
Country [138] 0 0
Hungary
State/province [138] 0 0
Komárom
Country [139] 0 0
Hungary
State/province [139] 0 0
Pécs
Country [140] 0 0
Hungary
State/province [140] 0 0
Siófok
Country [141] 0 0
Hungary
State/province [141] 0 0
Szeged
Country [142] 0 0
Hungary
State/province [142] 0 0
Százhalombatta
Country [143] 0 0
Hungary
State/province [143] 0 0
Törökbálint
Country [144] 0 0
India
State/province [144] 0 0
Calicut
Country [145] 0 0
India
State/province [145] 0 0
Coimbatore
Country [146] 0 0
India
State/province [146] 0 0
Guntur
Country [147] 0 0
India
State/province [147] 0 0
Hyderabad
Country [148] 0 0
India
State/province [148] 0 0
Jaipur
Country [149] 0 0
India
State/province [149] 0 0
Thane
Country [150] 0 0
India
State/province [150] 0 0
Vijayawada
Country [151] 0 0
Italy
State/province [151] 0 0
Cona
Country [152] 0 0
Italy
State/province [152] 0 0
Genova
Country [153] 0 0
Italy
State/province [153] 0 0
Milano
Country [154] 0 0
Italy
State/province [154] 0 0
Napoli
Country [155] 0 0
Italy
State/province [155] 0 0
Reggio Emilia
Country [156] 0 0
Italy
State/province [156] 0 0
Roma
Country [157] 0 0
Italy
State/province [157] 0 0
Rozzano
Country [158] 0 0
Japan
State/province [158] 0 0
Chuo-ku
Country [159] 0 0
Japan
State/province [159] 0 0
Fukuoka-shi
Country [160] 0 0
Japan
State/province [160] 0 0
Himeji-shi
Country [161] 0 0
Japan
State/province [161] 0 0
Hitachinaka-shi
Country [162] 0 0
Japan
State/province [162] 0 0
Joyo-shi
Country [163] 0 0
Japan
State/province [163] 0 0
Kawachinagano-shi
Country [164] 0 0
Japan
State/province [164] 0 0
Kishiwada-shi
Country [165] 0 0
Japan
State/province [165] 0 0
Kobe-shi
Country [166] 0 0
Japan
State/province [166] 0 0
Koto-ku
Country [167] 0 0
Japan
State/province [167] 0 0
Kure-shi
Country [168] 0 0
Japan
State/province [168] 0 0
Matsusaka-shi
Country [169] 0 0
Japan
State/province [169] 0 0
Mizunami-shi
Country [170] 0 0
Japan
State/province [170] 0 0
Nagaoka-shi
Country [171] 0 0
Japan
State/province [171] 0 0
Nagoya-shi
Country [172] 0 0
Japan
State/province [172] 0 0
Nishinomiya-shi
Country [173] 0 0
Japan
State/province [173] 0 0
Okayama-shi
Country [174] 0 0
Japan
State/province [174] 0 0
Osaka-shi
Country [175] 0 0
Japan
State/province [175] 0 0
Sagamihara-shi
Country [176] 0 0
Japan
State/province [176] 0 0
Sakai-shi
Country [177] 0 0
Japan
State/province [177] 0 0
Sakaide-shi
Country [178] 0 0
Japan
State/province [178] 0 0
Seto-shi
Country [179] 0 0
Japan
State/province [179] 0 0
Shinagawa-ku
Country [180] 0 0
Japan
State/province [180] 0 0
Toshima-ku
Country [181] 0 0
Japan
State/province [181] 0 0
Toyonaka-shi
Country [182] 0 0
Japan
State/province [182] 0 0
Ueda-shi
Country [183] 0 0
Japan
State/province [183] 0 0
Yanagawa-shi
Country [184] 0 0
Japan
State/province [184] 0 0
Yokohama-shi
Country [185] 0 0
Korea, Republic of
State/province [185] 0 0
Daegu
Country [186] 0 0
Korea, Republic of
State/province [186] 0 0
Jeonju-si
Country [187] 0 0
Korea, Republic of
State/province [187] 0 0
Seoul
Country [188] 0 0
Korea, Republic of
State/province [188] 0 0
Wonju-si
Country [189] 0 0
Mexico
State/province [189] 0 0
Guadalajara
Country [190] 0 0
Mexico
State/province [190] 0 0
Mérida
Country [191] 0 0
Mexico
State/province [191] 0 0
Veracruz
Country [192] 0 0
Netherlands
State/province [192] 0 0
Breda
Country [193] 0 0
Netherlands
State/province [193] 0 0
Leeuwarden
Country [194] 0 0
New Zealand
State/province [194] 0 0
Auckland
Country [195] 0 0
New Zealand
State/province [195] 0 0
Christchurch
Country [196] 0 0
New Zealand
State/province [196] 0 0
Dunedin
Country [197] 0 0
New Zealand
State/province [197] 0 0
Hamilton
Country [198] 0 0
Philippines
State/province [198] 0 0
Iloilo City
Country [199] 0 0
Philippines
State/province [199] 0 0
Los Baños
Country [200] 0 0
Philippines
State/province [200] 0 0
Marilao
Country [201] 0 0
Philippines
State/province [201] 0 0
Quezon City
Country [202] 0 0
Poland
State/province [202] 0 0
Bialystok
Country [203] 0 0
Poland
State/province [203] 0 0
Checiny
Country [204] 0 0
Poland
State/province [204] 0 0
Grodzisk Mazowiecki
Country [205] 0 0
Poland
State/province [205] 0 0
Katowice
Country [206] 0 0
Poland
State/province [206] 0 0
Ostrowiec Swietokrzyski
Country [207] 0 0
Poland
State/province [207] 0 0
Poznan
Country [208] 0 0
Poland
State/province [208] 0 0
Proszowice
Country [209] 0 0
Poland
State/province [209] 0 0
Rzeszów
Country [210] 0 0
Poland
State/province [210] 0 0
Warszawa
Country [211] 0 0
Poland
State/province [211] 0 0
Wielun
Country [212] 0 0
Poland
State/province [212] 0 0
Lódz
Country [213] 0 0
Spain
State/province [213] 0 0
Barcelona
Country [214] 0 0
Spain
State/province [214] 0 0
Hospitalet de Llobregat(Barcel
Country [215] 0 0
Spain
State/province [215] 0 0
Laredo
Country [216] 0 0
Spain
State/province [216] 0 0
Madrid
Country [217] 0 0
Spain
State/province [217] 0 0
Málaga
Country [218] 0 0
Spain
State/province [218] 0 0
Santander
Country [219] 0 0
Sweden
State/province [219] 0 0
Go¨teborg
Country [220] 0 0
Sweden
State/province [220] 0 0
Göteborg
Country [221] 0 0
Sweden
State/province [221] 0 0
Lund
Country [222] 0 0
Sweden
State/province [222] 0 0
Malmö
Country [223] 0 0
Sweden
State/province [223] 0 0
Stockholm
Country [224] 0 0
Turkey
State/province [224] 0 0
Adana
Country [225] 0 0
Turkey
State/province [225] 0 0
Istanbul
Country [226] 0 0
Turkey
State/province [226] 0 0
Izmir
Country [227] 0 0
Turkey
State/province [227] 0 0
Kocaeli
Country [228] 0 0
Turkey
State/province [228] 0 0
Mersin
Country [229] 0 0
United Kingdom
State/province [229] 0 0
Barnsley
Country [230] 0 0
United Kingdom
State/province [230] 0 0
Birmingham
Country [231] 0 0
United Kingdom
State/province [231] 0 0
Blackpool
Country [232] 0 0
United Kingdom
State/province [232] 0 0
Bradford
Country [233] 0 0
United Kingdom
State/province [233] 0 0
Chertsey
Country [234] 0 0
United Kingdom
State/province [234] 0 0
Cottingham
Country [235] 0 0
United Kingdom
State/province [235] 0 0
Leicester
Country [236] 0 0
United Kingdom
State/province [236] 0 0
Manchester
Country [237] 0 0
United Kingdom
State/province [237] 0 0
Oxford
Country [238] 0 0
United Kingdom
State/province [238] 0 0
Perth
Country [239] 0 0
United Kingdom
State/province [239] 0 0
Southampton
Country [240] 0 0
United Kingdom
State/province [240] 0 0
Stockton-on-Tees
Country [241] 0 0
United Kingdom
State/province [241] 0 0
Wishaw
Country [242] 0 0
Vietnam
State/province [242] 0 0
Hanoi
Country [243] 0 0
Vietnam
State/province [243] 0 0
Ho Chi Minh city
Country [244] 0 0
Vietnam
State/province [244] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (=300/µL).

Eligible patients must have a history of =2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count.

The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.
Trial website
https://clinicaltrials.gov/study/NCT04053634
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gerard Criner, MD
Address 0 0
Temple University School of Medicine, 3401 North Broad Street, Suite 745 PP, Philadelphia, PA 19140
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04053634